Global Health: Science and Practice (GHSP)
Vol. 10, No. 2 April 28, 2022
http://www.ghspjournal.org/content/current

VIEWPOINTS
Open Access
Strategies to Promote Health System Strengthening and Global Health Security at the Subnational Level in a World Changed by COVID-19
Martin Alilio, Neetu Hariharan, Elizabeth Lugten, Kama Garrison, Rhea Bright, Wilberforce Owembabazi, Uwem Inyang, Saad El-Din Hassan and Kelly Saldana
Global Health: Science and Practice April 2022, 10(2):e2100478; https://doi.org/10.9745/GHSP-D-21-00478
Structural weaknesses in national health systems have led to huge variations in responses to COVID-19. This calls for a unified approach to health security and essential health services as public health threats and the expectation for health care systems to provide improved access and services at affordable cost increases.

Global Health: Science and Practice (GHSP)
Vol. 10, No. 2 April 28, 2022
http://www.ghspjournal.org/content/current

ORIGINAL ARTICLES
Open Access
Cost of Delivering Tetanus Toxoid and Tetanus-Diphtheria Vaccination in Vietnam and the Budget Impact of Proposed Changes to the Schedule
Vu Quynh Mai, Laura Boonstoppel, Kelsey Vaughan, Carl Schutte, Annette Ozaltin, Duong Thi Hong, Nguyen Mai Khanh, Hoang Manh Thang, Tran Tuan Anh and Hoang Van Minh
Global Health: Science and Practice April 2022, 10(2):e2100482; https://doi.org/10.9745/GHSP-D-21-00482
This study shows that replacing tetanus toxoid vaccination in Vietnam for girls aged 15–16 years in high-risk areas with routine tetanus-diphtheria vaccination for children aged 7 years mainly through a school-based delivery strategy will likely result in immunization cost savings.

Global Public Health
Volume 17, Issue 5 (2022)
http://www.tandfonline.com/toc/rgph20/current

Review Article
What makes global healthcare partnerships successful? A systematic review
Regan Guilfoyle, Alexander D. Morzycki & Abdullah Saleh
Pages: 662-671
Published online: 09 Mar 2021
ABSTRACT
Academic communities are increasingly involved in efforts to address the overwhelming burden of disease in low-middle income countries. There is, however, little research dedicated to understanding the best approach to creating a successful and sustainable global healthcare project. Our objective was to review the shared characteristics of successful healthcare partnerships between high- and low-middle income countries. Two independent reviewers conducted a systematic review. Articles, describing collaborative, healthcare partnerships between a high- and low-middle income countries between 1910 and September 2018, were included. Twenty-six articles were included. The majority of collaborations were initiated by either the host institution or as a joint decision between institutions. The primary goal of these collaborations revolved around medical education/training and curriculum development. Two partnerships, after more than a decade of collaboration, had achieved a self-sustaining programme. Lack of funding was identified as a major barrier to sustainability. Successful global healthcare partnerships require true collaboration and equal participation of all partners. Funding should be secured prior to programme development in anticipation of a minimum 10-year project. A minimum list of guidelines has been proposed to improve the chances of both a successful and sustainable collaboration.

Health Policy and Planning
Volume 37, Issue 4, April 2022
https://academic.oup.com/heapol/issue/37/4

REVIEWS
Seroprevalence and risk factors of COVID-19 in healthcare workers from 11 African countries: a scoping review and appraisal of existing evidence
Sophie Alice Müller, Rebekah Ruth Wood, Johanna Hanefeld, Charbel El-Bcheraoui
Health Policy and Planning, Volume 37, Issue 4, April 2022, Pages 505–513, https://doi.org/10.1093/heapol/czab133

Health Policy and Planning
Volume 37, Issue 4, April 2022
https://academic.oup.com/heapol/issue/37/4

A systematic review of scope and quality of health economic evaluations conducted in Ethiopia
Daniel Erku, Amanual G Mersha, Eskinder Eshetu Ali, Gebremedhin B Gebretekle, Befikadu L Wubishet
Health Policy and Planning, Volume 37, Issue 4, April 2022, Pages 514–522, https://doi.org/10.1093/heapol/czac005

Health Policy and Planning
Volume 37, Issue 4, April 2022
https://academic.oup.com/heapol/issue/37/4

What makes working together work? A scoping review of the guidance on North–South research partnerships
Shirine Voller, Joanna Schellenberg, Primus Chi, Nicki Thorogood
Health Policy and Planning, Volume 37, Issue 4, April 2022, Pages 523–534, https://doi.org/10.1093/heapol/czac008

International Journal of Human Rights in Healthcare
Volume 15 Issue 2, 2022
https://www.emerald.com/insight/publication/issn/2056-4902/vol/15/iss/2

Table of Contents
The role of social media in promoting citizenship values of international students during the COVID-19 global health crisis
Thelal Iqab Oweis
The purpose of this study, accordingly, is to not only offer insights about Arab international students’ stress management and adjustment mechanisms while abroad but also bring to light the extent to which these digital citizens’ use of social media networks reinforces their citizenship values and preserves their national identity during the COVID-19 global health crisis.

JAMA
April 26, 2022, Vol 327, No. 16, Pages 1527-1624
https://jamanetwork.com/journals/jama/currentissue

Research Letter
Secondary Attack Rates for Omicron and Delta Variants of SARS-CoV-2 in Norwegian Households
Silje B. Jørgensen, MD, PhD; Karin Nygård, PhD; Oliver Kacelnik, MD, PhD; et al.
free access has active quiz
JAMA. 2022;327(16):1610-1611. doi:10.1001/jama.2022.3780
This nationwide registry data study from Norway assesses the secondary attack rate of SARS-CoV-2 variants Delta and Omicron in an effort to estimate the transmissibility of the Omicron variant.

JAMA
April 26, 2022, Vol 327, No. 16, Pages 1527-1624
https://jamanetwork.com/journals/jama/currentissue

Myocarditis Following a Third BNT162b2 Vaccination Dose in Military Recruits in Israel
Limor Friedensohn, MD; Dan Levin, MD; Maggie Fadlon-Derai, MHA; et al.
free access has active quiz
JAMA. 2022;327(16):1611-1612. doi:10.1001/jama.2022.4425
This study assessed whether a third vaccine dose was associated with the risk of myocarditis among military personnel in Israel.

JAMA
April 26, 2022, Vol 327, No. 16, Pages 1527-1624
https://jamanetwork.com/journals/jama/currentissue

Viewpoint
Attacks on Health Care in the War in UkraineInternational Law and the Need for Accountability
Lawrence O. Gostin, JD; Leonard S. Rubenstein, JD
free access has audio
JAMA. 2022;327(16):1541-1542. doi:10.1001/jama.2022.6045
This Viewpoint from Gostin and Rubenstein examine the violence against health care workers and institutions in the war in Ukraine and potential paths to hold those perpetuating such attacks accountable.
JAMA Medical News Audio: Ukrainian Doctors Share Current Experiences
Editorial
Catastrophic Health Consequences of the War in Ukraine
Phil B. Fontanarosa, MD, MBA; Annette Flanagin, RN, MA; Robert M. Golub, MD

JAMA
April 26, 2022, Vol 327, No. 16, Pages 1527-1624
https://jamanetwork.com/journals/jama/currentissue

Medical News & Perspectives
Clinical Trials Disrupted During War in Ukraine
Rita Rubin, MA
free access has audio
JAMA. 2022;327(16):1535-1536. doi:10.1001/jama.2022.5571
This Medical News feature describes how the Russian invasion has disrupted clinical trials in Ukraine as well as Russia.

JAMA Network
COVID-19 Update April 30, 2022

These articles on COVID-19 were published across the JAMA Network in the last week.

Journal of Pharmaceutical Policy and Practice
https://joppp.biomedcentral.com/
[Accessed 30 Apr 2022]

COVID-19 vaccines: awareness, attitude and acceptance among undergraduate University students
The myths and conspiracy theories on the COVID-19 vaccine cause people to be hesitant and maleficent towards the vaccine.
Authors: Firew Asres and Belachew Umeta
Citation: Journal of Pharmaceutical Policy and Practice 2022 15:32
Content type: Research Published on: 26 April 2022

The Lancet
Apr 30, 2022 Volume 399 Number 10336 p1669-1752, e39-e41
https://www.thelancet.com/journals/lancet/issue/current

Articles
Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial
Trong Toan Nguyen, et al.

The Lancet
Apr 30, 2022 Volume 399 Number 10336 p1669-1752, e39-e41
https://www.thelancet.com/journals/lancet/issue/current

Series
Optimising Child and Adolescent Health and Development
Health and development from preconception to 20 years of age and human capital
Robert E Black, et al.

The Lancet
Apr 30, 2022 Volume 399 Number 10336 p1669-1752, e39-e41
https://www.thelancet.com/journals/lancet/issue/current

Optimising Child and Adolescent Health and Development
Effects of early-life poverty on health and human capital in children and adolescents: analyses of national surveys and birth cohort studies in LMICs
Cesar G Victora, et al.

Nature
Volume 604 Issue 7907, 28 April 2022
https://www.nature.com/nature/volumes/604/issues/7907

Article | 07 March 2022 | Open Access
SARS-CoV-2 is associated with changes in brain structure in UK Biobank
Gwenaëlle Douaud, Soojin Lee, Stephen M. Smith
After infection with SARS-CoV-2, individuals show a greater reduction in grey matter thickness and tissue contrast in the orbitofrontal cortex and parahippocampal gyrus; greater changes in markers of tissue damage in regions that are functionally connected to the primary olfactory cortex; and a greater reduction in global brain size.

Nature
Volume 604 Issue 7907, 28 April 2022
https://www.nature.com/nature/volumes/604/issues/7907

Article
Climate change increases cross-species viral transmission risk
Colin J. Carlson, et al.
Published: 28 April 2022
Abstract
At least 10,000 virus species have the capacity to infect humans, but at present, the vast majority are circulating silently in wild mammals1,2. However, climate and land use change will produce novel opportunities for viral sharing among previously geographically-isolated species of wildlife3,4. In some cases, this will facilitate zoonotic spillover—a mechanistic link between global environmental change and disease emergence. Here, we simulate potential hotspots of future viral sharing, using a phylogeographic model of the mammal-virus network, and projections of geographic range shifts for 3,139 mammal species under climate change and land use scenarios for the year 2070. We predict that species will aggregate in new combinations at high elevations, in biodiversity hotspots, and in areas of high human population density in Asia and Africa, driving the novel cross-species transmission of their viruses an estimated 4,000 times. Because of their unique dispersal capacity, bats account for the majority of novel viral sharing, and are likely to share viruses along evolutionary pathways that will facilitate future emergence in humans. Surprisingly, we find that this ecological transition may already be underway, and holding warming under 2 °C within the century will not reduce future viral sharing. Our findings highlight an urgent need to pair viral surveillance and discovery efforts with biodiversity surveys tracking species’ range shifts, especially in tropical regions that harbor the most zoonoses and are experiencing rapid warming.

New England Journal of Medicine
April 28, 2022 Vol. 386 No. 17
https://www.nejm.org/toc/nejm/medical-journal

Original Articles
Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting O. Magen and Others

New England Journal of Medicine
April 28, 2022 Vol. 386 No. 17
https://www.nejm.org/toc/nejm/medical-journal

Review Article
Understanding Vaccine Safety and the Roles of the FDA and the CDC H.C. Meissner

New England Journal of Medicine
April 28, 2022 Vol. 386 No. 17
https://www.nejm.org/toc/nejm/medical-journal

Editorials
Covid-19 Boosters — Where from Here? P.A. Offit
n December 10, 2020, Pfizer presented results from a 36,000-person, two-dose, prospective, placebo-controlled trial of its Covid-19 messenger RNA (mRNA) vaccine, BNT162b2, to the Food and Drug Administration (FDA).¹ The vaccine was 95% effective at preventing severe illness in all age groups, independent of coexisting conditions or racial or ethnic background. A remarkable result. Six months later, studies showed that protection against severe disease was holding up.² The results of these epidemiologic studies were consistent with those of immunologic studies showing long-lived, high frequencies of Covid-19–specific memory B and T cells, which mediate protection against severe disease.³

In September 2021, 10 months after the BNT162b2 vaccine had become available, Israeli researchers found that protection against severe illness in people 60 years of age or older was enhanced by a third dose.⁴ In response, the Centers for Disease Control and Prevention (CDC) recommended that people 65 years of age or older should receive three doses of an mRNA vaccine.

In a study now reported in the Journal,⁵ Israeli researchers found that in a study population with a median age of 72 years, protection against severe disease was further enhanced by a fourth dose of mRNA vaccine during the wave of infections caused by the B.1.1.529 (omicron) variant of SARS-CoV-2. These findings were considered by the FDA and CDC in their decision-making process regarding the use of an additional booster dose of mRNA vaccine for people 50 years of age or older.

What about booster dosing for persons who are younger? One year after the BNT162b2 vaccine became available, studies in the United States showed that a third dose of vaccine also enhanced protection against severe disease for people as young as 18 years of age.6,7 Unfortunately, these studies did not stratify patients according to whether they had coexisting conditions. Therefore, it was unclear who among these younger age groups most benefited from an additional dose. Nonetheless, the CDC later recommended that everyone 12 years of age or older should receive three doses of BNT162b2, regardless of whether risk factors were present. This universal booster recommendation led some summer camps, high schools, universities, hospitals, and businesses to require three doses of mRNA vaccine. In February 2022, in a study that did not support the booster recommendation for children, CDC researchers found that two doses of BNT162b2 induced long-lived protection against serious illness in children 12 to 18 years of age.⁸

In addition to protection against severe disease, the initial phase 3 trial of BNT162b2 — which was performed over a period of several months — also showed 95% protection against mild illness.¹ Unlike protection against severe illness, however, protection against mild illness, which is mediated by high titers of virus-specific neutralizing antibodies at the time of exposure, declined after 6 months, as would have been expected.² In response, studies by Pfizer were published in which a booster dose was shown to restore protection against mild illness⁹; unfortunately, this protection did not persist for more than a few months.⁶ Short-lived protection against mild illness will limit the ability of booster dosing to lessen transmission.

People are now confused about what it means to be fully vaccinated. It is easy to understand how this could happen. Arguably, the most disappointing error surrounding the use of Covid-19 vaccines was the labeling of mild illnesses or asymptomatic infections after vaccination as “breakthroughs.” As is true for all mucosal vaccines, the goal is to protect against serious illness — to keep people out of the hospital, intensive care unit, and morgue. The term “breakthrough,” which implies failure, created unrealistic expectations and led to the adoption of a zero-tolerance strategy for this virus. If we are to move from pandemic to endemic, at some point we are going to have to accept that vaccination or natural infection or a combination of the two will not offer long-term protection against mild illness.

In addition, because boosters are not risk-free, we need to clarify which groups most benefit. For example, boys and men between 16 and 29 years of age are at increased risk for myocarditis caused by mRNA vaccines.¹⁰ And all age groups are at risk for the theoretical problem of an “original antigenic sin” — a decreased ability to respond to a new immunogen because the immune system has locked onto the original immunogen. An example of this phenomenon can be found in a study of nonhuman primates showing that boosting with an omicron-specific variant did not result in higher titers of omicron-specific neutralizing antibodies than did boosting with the ancestral strain.¹¹ This potential problem could limit our ability to respond to a new variant.

It is now incumbent on the CDC to determine who most benefits from booster dosing and to educate the public about the limits of mucosal vaccines. Otherwise, a zero-tolerance strategy for mild or asymptomatic infection, which can be implemented only with frequent booster doses, will continue to mislead the public about what Covid-19 vaccines can and cannot do.

PLoS Biology
https://journals.plos.org/plosbiology/
(Accessed 30 Apr 2022)

One step closer to a transmissible vaccine for rabies virus
Scott L. Nuismer
Primer | published 20 Apr 2022 PLOS Biology
https://doi.org/10.1371/journal.pbio.3001607

PLoS Medicine
http://www.plosmedicine.org/
(Accessed 30 Apr 2022)

Nonregistration, discontinuation, and nonpublication of randomized trials: A repeated metaresearch analysis
Benjamin Speich, Dmitry Gryaznov, Jason W. Busse, Viktoria L. Gloy, Szimonetta Lohner, Katharina Klatte, Ala Taji Heravi, Nilabh Ghosh, Hopin Lee, Anita Mansouri, Ioana R. Marian, Ramon Saccilotto, Edris Nury, Benjamin Kasenda, Elena Ojeda–Ruiz, Stefan Schandelmaier, Yuki Tomonaga, Alain Amstutz, Christiane Pauli–Magnus, Karin Bischoff, Katharina Wollmann, Laura Rehner, Joerg J. Meerpohl, Alain Nordmann, Jacqueline Wong, Ngai Chow, Patrick Jiho Hong, Kimberly Mc Cord – De Iaco, Sirintip Sricharoenchai, Arnav Agarwal, Matthias Schwenkglenks, Lars G. Hemkens, Erik von Elm, Bethan Copsey, Alexandra N. Griessbach, Christof Schönenberger, Dominik Mertz, Anette Blümle, Belinda von Niederhäusern, Sally Hopewell, Ayodele Odutayo, Matthias Briel
Research Article | published 27 Apr 2022 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1003980

PLoS Medicine
http://www.plosmedicine.org/
(Accessed 30 Apr 2022)

Social justice now for an equitable tomorrow: Reflections from the Consortium of Universities for Global Health Conference 2022
Beryne Odeny, Callam Davidson
Perspective | published 22 Apr 2022 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1003995

PLoS One
http://www.plosone.org/
[Accessed 30 Apr 2022]

Research Article
Age and sex associations of SARS-CoV-2 antibody responses post BNT162b2 vaccination in healthcare workers: A mixed effects model across two vaccination periods
Cleo Anastassopoulou, Dimitra Antoni, Yiannis Manoussopoulos, Panagiotis Stefanou, Sofia Argyropoulou, Georgia Vrioni, Athanasios Tsakris
Research Article | published 29 Apr 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0266958

PLoS One
http://www.plosone.org/
[Accessed 30 Apr 2022]

Human drone interaction in delivery of medical supplies: A scoping review of experimental studies
Franziska Stephan, Nicole Reinsperger, Martin Grünthal, Denny Paulicke, Patrick Jahn
Research Article | published 28 Apr 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0267664

PLoS One
http://www.plosone.org/
[Accessed 30 Apr 2022]

Vaccination against misinformation: The inoculation technique reduces the continued influence effect
Mikołaj Buczel, Paulina D. Szyszka, Adam Siwiak, Malwina Szpitalak, Romuald Polczyk
Research Article | published 28 Apr 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0267463

PLoS One
http://www.plosone.org/
[Accessed 30 Apr 2022]

Responsiveness of open innovation to COVID-19 pandemic: The case of data for good
Francesco Scotti, Francesco Pierri, Giovanni Bonaccorsi, Andrea Flori
Research Article | published 26 Apr 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0267100

Risk Management and Healthcare Policy
https://www.dovepress.com/risk-management-and-healthcare-policy-archive56
[Accessed 30 Apr 2022]

Commentary
Vaccine Inequity and Hesitancy: A Vicious Cycle Undermining the Fight Against the COVID-19 Pandemic
Gudina EK, Mekonnen Z, Yilma D
Risk Management and Healthcare Policy ²⁰²², 15:865-869
Published Date: 29 April 2022

Risk Management and Healthcare Policy
https://www.dovepress.com/risk-management-and-healthcare-policy-archive56
[Accessed 30 Apr 2022]

Original Research
Chinese University Students’ Awareness and Acceptance of the COVID-19 Vaccine: A Cross-Sectional Study
Li S, Gao Z, Zhong M, Yu Z, Li J, Bi H
Risk Management and Healthcare Policy ²⁰²², 15:845-864
Published Date: 29 April 2022

Risk Management and Healthcare Policy
https://www.dovepress.com/risk-management-and-healthcare-policy-archive56
[Accessed 30 Apr 2022]

Review
COVID-19 in Veterans: A Narrative Review
Chuang YC, Tsai HW, Liu SA, Wu MJ, Liu PY
Risk Management and Healthcare Policy ²⁰²², 15:805-815
Published Date: 26 April 2022

Science
Volume 376| Issue 6592| 29 Apr 2022
https://www.science.org/toc/science/current

Policy Forum
A global system for the next generation of vaccines
BY Nimalan Arinaminpathy, Chadi M. Saad-Roy, Qiqi Yang, Isa Ahmad, Prashant Yadav, Bryan Grenfell
28 Apr 2022: 462-464
FULL ACCESS
COVID-19 has shown that hurdles can be overcome
The rapid development of vaccines against COVID-19 raises questions about what could be achieved in vaccines to other major diseases. Influenza presents an important case study; it is one of the few infections that causes substantial public health burden in its endemic form while also having proven pandemic potential. We offer a first step in bringing together the value proposition of future influenza vaccines considering two key characteristics: the breadth of protection that vaccines offer (against individual strains, all strains within a subtype, multiple subtypes, or all subtypes) and the duration for which protection remains effective (see the figure). We examine implications of these characteristics, from both epidemiologic and economic perspectives, and discuss how a future market for influenza vaccines might best align public health and economic incentives. Although many of these factors are specific to influenza, we consider comparisons with other major infections, such as tuberculosis and COVID-19.

Science and Engineering Ethics
Volume 28, issue 2, April 2022
https://link.springer.com/journal/11948/volumes-and-issues/28-2

Original Research/Scholarship – Open Access
Standards of Conducts for Biostatisticians and Stem Cell Researchers: A Call for Self-formulated Aspirational Ethics Over Built-in Prohibitive Ethics
Keiko Sato & Mika Suzuki
Published: 17 March 2022
Abstract
We proposed the Standards of Conducts to provide a general framework that will serve as the basis for guiding each biostatistician and stem cell researcher to formulate their personal standards, rather than as rules with which they are required to comply. Given the responsibility and characteristics of their work, they are expected to maintain independence and work autonomously as professionals. Each of the Standards of Conducts comprises a preamble, mission and values to uphold, Standards of Conducts (10 items), and background. When one internalizes “self-formulated” standards, to make excuses for oneself would be akin to a self-betrayal; responsible actions can be anticipated. If one begins and continues to consider “who I am and what do I work for,” this will become their inner energy, and a source of motivation and pride to inspire oneself. In addition, this aspirational style might help citizens to recognize the autonomous stance of the professional body and that they share the same values.

Social Science & Medicine
Volume 298 April 2022
https://www.sciencedirect.com/journal/social-science-and-medicine/vol/298/suppl/C

Research article Open access
Vaccine anxieties, vaccine preparedness: Perspectives from Africa in a Covid-19 era
Melissa Leach, Hayley MacGregor, Grace Akello, Lawrence Babawo, … Khoudia Sow
Article 114826

Social Science & Medicine
Volume 298 April 2022
https://www.sciencedirect.com/journal/social-science-and-medicine/vol/298/suppl/C

Research article Full text access
Applying an extended protection motivation theory to predict Covid-19 vaccination intentions and uptake in 50–64 year olds in the UK
Bethany Griffin, Mark Conner, Paul Norman
Article 114819

Social Science & Medicine
Volume 298 April 2022
https://www.sciencedirect.com/journal/social-science-and-medicine/vol/298/suppl/C

Research article Abstract only
Vaccine discourse in white nationalist online communication: A mixed-methods computational approach
Dror Walter, Yotam Ophir, Ayse D. Lokmanoglu, Meredith L. Pruden
Article 114859

Social Science & Medicine
Volume 298 April 2022
https://www.sciencedirect.com/journal/social-science-and-medicine/vol/298/suppl/C

Research article Open access
The path towards herd immunity: Predicting COVID-19 vaccination uptake through results from a stated choice study across six continents
Stephane Hess, Emily Lancsar, Petr Mariel, Jürgen Meyerhoff, … Mark H.P. Zuidgeest
Article 114800

Social Science & Medicine
Volume 298 April 2022
https://www.sciencedirect.com/journal/social-science-and-medicine/vol/298/suppl/C

Research article Full text access
Inside the ‘black box’ of COVID-19 vaccination beliefs: Revealing the relative importance of public confidence and news consumption habits
Jennifer A. Lueck, Timothy Callaghan
Article 114874

Systematic Reviews
https://systematicreviewsjournal.biomedcentral.com/articles
[Accessed 30 Apr 2022]

Strategies to overcome vaccine hesitancy: a systematic review
Vaccination, albeit a necessity in the prevention of infectious diseases, requires appropriate strategies for addressing vaccine hesitancy at an individual and community level. However, there remains a glaring…
Authors: Prem Singh, Pritu Dhalaria, Satabdi Kashyap, Gopal Krishna Soni, Partha Nandi, Shreeparna Ghosh, Mrinal Kar Mohapatra, Apurva Rastogi and Divya Prakash
Citation: Systematic Reviews 2022 11:78
Content type: Research Published on: 26 April 2022

Tropical Medicine & International Health
Volume 27, Issue 4 Pages: i-iv, 337-465 April 2022
https://onlinelibrary.wiley.com/toc/13653156/current

RESEARCH ARTICLES
COVID-19 vaccine acceptability among healthcare workers in Ethiopia: Do we practice what we preach?
Daniel Yilma, Rezika Mohammed, Seid Getahun Abdela, Wendemagegn Enbiale, Fasil Seifu, Myrthe Pareyn, Laurens Liesenborghs, Johan van Griensven, Saskia van Henten
Pages: 418-425
First Published: 01 March 2022

Vaccine
Volume 40, Issue 16 Pages 2365-2472 (6 April 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/16

Research article Full text access
Sociodemographic and psychological correlates of COVID-19 vaccine hesitancy and resistance in the young adult population in Italy
Ughetta Moscardino, Pasquale Musso, Cristiano Inguglia, Chiara Ceccon, … Cécile Rousseau
Pages 2379-2387

Vaccine
Volume 40, Issue 16 Pages 2365-2472 (6 April 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/16

Research article Open access
Public health facility quality and child immunization outcomes in rural India: A decomposition analysis
Amit Summan, Arindam Nandi, Emily Schueller, Ramanan Laxminarayan
Pages 2388-2398

Vaccine
Volume 40, Issue 16 Pages 2365-2472 (6 April 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/16

Research article Abstract only
Policy and practice of checking vaccination status at school in 2018, a global overview
Katrin Sadigh, Garrett Fox, Nino Khetsuriani, Hongjiang Gao, … Kirsten Ward
Pages 2432-2441

Vaccine
Volume 40, Issue 16 Pages 2365-2472 (6 April 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/16

Research article Full text access
COVID-19 vaccine intention among young adults: Comparative results from a cross-sectional study in Canada and France
Pierre-julien Coulaud, Aidan Ablona, Naseeb Bolduc, Danya Fast, … Rod Knight
Pages 2442-2456

Vaccine
Volume 40, Issue 16 Pages 2365-2472 (6 April 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/16

Research article Full text access
Public opinion on global distribution of COVID-19 vaccines: Evidence from two nationally representative surveys in Germany and the United States
Matthias Klumpp, Ida G. Monfared, Sebastian Vollmer
Pages 2457-2461

Pre-Print Servers

Gates Open Research
https://gatesopenresearch.org/browse/articles
No new digest content identified.

medRxiv
https://www.medrxiv.org/content/about-medrxiv
medRxiv is a free online archive and distribution server for complete but unpublished manuscripts (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information. medRxiv is for the distribution of preprints – complete but unpublished manuscripts – that describe human health research conducted, analyzed, and interpreted according to scientific principles…

The impact of COVID-19 pandemic on influenza surveillance: a systematic review and meta-analysis
Sasidharanpillai Sabeena, N Ravishankar, Sudandiradas Robin
medRxiv 2022.03.31.22273236; doi: https://doi.org/10.1101/2022.03.31.22273236 Revision

Higher contact among vaccinated can be a mechanism for negative vaccine effectiveness
Korryn Bodner, Jesse Knight, Mackenzie A. Hamilton, Sharmistha Mishra
medRxiv 2022.04.25.22274266; doi: https://doi.org/10.1101/2022.04.25.22274266 Revision

Which countries need COVID-19 vaccines the most? Development of a prioritisation tool
Vageesh Jain, Rifat Atun, Paul Hansen, Paula Lorgelly
medRxiv 2022.04.27.22274377; doi: https://doi.org/10.1101/2022.04.27.22274377

A systematic review of the experiences of minority language users in health and social care research
Dr Llinos Haf Spencer, Mrs Beryl Ann Cooledge, Dr Zoe Hoare
medRxiv 2022.04.27.22273307; doi: https://doi.org/10.1101/2022.04.27.22273307

Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco
Yaowen Zhang, Jihane Belayachi, Yunkai Yang, Qiang Fu, Lance Rodewald, Hongling Li, Bing Yan, Ying Wang, Yanna Shen, Qian Yang, Weiyun Mu, Rong Tang, Chen Su, Tianfang Xu, Majdouline Obtel, Abdelkader Mhayi, Rachid Razine, Redouane Abouqal, Yuntao Zhang, Xiaoming Yang
medRxiv 2022.04.23.22274112; doi: https://doi.org/10.1101/2022.04.23.22274112

Mondo: Unifying diseases for the world, by the world
Nicole A Vasilevsky, Nicolas A Matentzoglu, Sabrina Toro, Joseph E Flack IV, Harshad Hegde, Deepak R Unni, Gioconda F Alyea, Joanna S Amberger, Larry Babb, James P Balhoff, Taylor I Bingaman, Gully A Burns, Orion J Buske, Tiffany J Callahan, Leigh C Carmody, Paula Carrio Cordo, Lauren E Chan, George S Chang, Sean L Christiaens, Michel Dumontier, Laura E Failla, May J Flowers, H. Alpha Garrett Jr., Jennifer L Goldstein, Dylan Gration, Tudor Groza, Marc Hanauer, Nomi L Harris, Jason A Hilton, Daniel S Himmelstein, Charles Tapley Hoyt, Megan S Kane, Sebastian Köhler, David Lagorce, Abbe Lai, Martin Larralde, Antonia Lock, Irene López Santiago, Donna R Maglott, Adriana J Malheiro, Birgit H M Meldal, Monica C Munoz-Torres, Tristan H Nelson, Frank W Nicholas, David Ochoa, Daniel P Olson, Tudor I Oprea, David Osumi-Sutherland, Helen Parkinson, Zoë May Pendlington, Ana Rath, Heidi L Rehm, Lyubov Remennik, Erin R Riggs, Paola Roncaglia, Justyne E Ross, Marion F Shadbolt, Kent A Shefchek, Morgan N Similuk, Nicholas Sioutos, Damian Smedley, Rachel Sparks, Ray Stefancsik, Ralf Stephan, Andrea L Storm, Doron Stupp, Gregory S Stupp, Jagadish Chandrabose Sundaramurthi, Imke Tammen, Darin Tay, Courtney L Thaxton, Eloise Valasek, Jordi Valls-Margarit, Alex H Wagner, Danielle Welter, Patricia L Whetzel, Lori L Whiteman, Valerie Wood, Colleen H Xu, Andreas Zankl, Xingmin Aaron Zhang, Christopher G Chute, Peter N Robinson, Christopher J Mungall, Ada Hamosh, Melissa A Haendel
medRxiv 2022.04.13.22273750; doi: https://doi.org/10.1101/2022.04.13.22273750 Revision

Strengthening vaccination delivery system resilience in the context of protracted humanitarian crisis: a realist-informed systematic review
Sharif A. Ismail, Sze Tung Lam, Sadie Bell, Fouad M. Fouad, Karl Blanchet, Josephine Borghi
medRxiv 2022.04.21.22273340; doi: https://doi.org/10.1101/2022.04.21.22273340 Revision

Wellcome Open Research [to 30 Apr 2022]
https://wellcomeopenresearch.org/browse/articles
[Accessed 30 Apr 2022]

Wellcome Open Research provides all Wellcome researchers with a place to rapidly publish any results they think are worth sharing. All articles benefit from rapid publication, transparent peer review and editorial guidance on making all source data openly available.

Research Article metrics
Revised
What are the active ingredients of ‘arts in health’ activities? Development of the INgredients iN ArTs in hEalth (INNATE) Framework [version 2; peer review: 1 approved, 1 approved with reservations]
Katey Warran, Alexandra Burton, Daisy Fancourt
Peer Reviewers Gunter Kreutz; Melissa Forbes
Funders
Wellcome Trust
Leverhulme Trust
UK Research and Innovation
LATEST VERSION PUBLISHED 29 Apr 2022

Think Tanks
 
 
Brookings [to 30 Apr 2022]
http://www.brookings.edu/
Accessed 30 Apr 2022
Latest Research
Essay
Lessons learned from support to business during COVID-19
Gabriel Chodorow-Reich, Ben Iverson, and Adi Sunderam
Wednesday, April 27, 2022
 
 
Essay
Lessons learned from expanded unemployment insurance during COVID-19
Peter Ganong, Fiona Greig, Pascal Noel, Daniel M. Sullivan, and Joseph Vavra
Wednesday, April 27, 2022
 
 
Essay
Lessons learned from the use of nontraditional data during COVID-19
Tomaz Cajner, Laura J. Feiveson, Christopher J. Kurz, and Stacey Tevlin
Wednesday, April 27, 2022

Essay
Lessons learned from support for the state and local sector during COVID-19
Louise Sheiner
Wednesday, April 27, 2022

Essay
Lessons learned from the COVID-19 policy response and child well-being
Anna Aizer and Claudia Persico
Wednesday, April 27, 2022
 
 
Center for Global Development [to 30 Apr 2022]
https://www.cgdev.org/
Research [Selected]
BRIEFS
ABCs of the IFIs: Understanding IDA20
Jocilyn Estes and Erin Collinson
April 29, 2022
With the COVID-19 pandemic hitting government balance sheets especially hard in low-income countries, the World Bank’s shareholders—including the United States—agreed to an advance replenishment of its grant and low-interest loan window, the International Development Association (IDA). By holding a …

BRIEFS
Understanding the Cost-Effectiveness of COVID-19 Vaccination in Nigeria
Benjamin S.C. Uzochukwu et al.
April 28, 2022
COVID-19 has disrupted health systems across the globe. Nigeria reported its first COVID-19 case in February 2020, and, since then, the government has rolled out four vaccines to help control the pandemic—Moderna, Oxford-Astra Zeneca (AZ), Johnson & Johnson (J&J) and Pfizer-BioNTech.

BRIEFS
Understanding the Cost-Effectiveness of COVID-19 Vaccination in Ethiopia
Anthony McDonnell et al.
April 28, 2022
COVID-19 radically changed most people’s lives in 2020, including across Africa. In Ethiopia, the disruption started with school closing, and other restrictions soon followed. Despite these efforts to contain the virus, Ethiopia—like almost all countries—suffered significant health impacts. It has r…
 
 
Chatham House [to 30 Apr 2022]
https://www.chathamhouse.org/
Accessed 30 Apr 2022
[No new digest content identified]
 
 
CSIS [to 30 Apr 2022]
https://www.csis.org/
Accessed 30 Apr 2022
Transcript
Equity in Immunization Services to Ensure “A Long Life for All”
April 29, 2022

Podcast Episode
Covid, Ukraine, and the New Geopolitical Logic
April 28, 2022 | By H. Andrew Schwartz, J. Stephen Morrison

Report
Securing Medical Supply Chains with Trusted Trade Partners
April 29, 2022 | Meredith Broadbent A new report from CSIS assesses the potential of nearshoring medical supply chains to neighbors in the Americas, using the case studies of Canada, Brazil, Mexico, and Colombia.

 
 
Kaiser Family Foundation
https://www.kff.org/search/?post_type=press-release
Accessed 30 Apr 2022
Accessed 30 Apr 2022
[No new digest content identified]
 
 
ODI [Overseas Development Institute] [to 30 Apr 2022]
https://odi.org/en/publications/
Publications
Accessed 30 Apr 2022
[No new digest content identified]
 
 
Rand [to 30 Apr 2022]
https://www.rand.org/pubs.html
Reports, Selected Journal Articles
Report
A Risk Assessment of National Critical Functions During COVID-19: Challenges and Opportunities
This report presents a framework for assessing risk that the coronavirus disease 2019 (COVID-19) poses to the National Critical Functions, describes challenges in implementing the framework, and provides recommendations for improving it.
Apr 26, 2022
Andrew Lauland, Benjamin Lee Preston, Kristin J. Leuschner, Michelle E. Miro, Liam Regan, Scott R. Stephenson, Rachel Steratore, Aaron Strong, Jonathan W. Welburn, Jeffrey B. Wenger
 
 
Urban Institute [to 30 Apr 2022]
https://www.urban.org/publications
Research Publications
Brief
COVID-19 and the System Resilience of Public Education: A View from North Carolina
April 28, 2022

Vaccines and Global Health: The Week in Review is a weekly digest  summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated with the current issue date

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

– pdf version:  A pdf of the current issue is available here:

– blog edition: comprised of the approx. 35+ entries posted below.

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy